Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT06710717RecruitingPhase 1
CD19 CAR T-cells for severe lupus
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Bandar Tun Razak, Kuala LumpurAges 18–65 - NCT06711705RecruitingPhase 2
Elranatamab for relapsed or refractory multiple myeloma
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06712121RecruitingPhase 2
Venetoclax plus decitabine for relapsed or refractory T-ALL
This trial tests the combination of two drugs, venetoclax and decitabine, for people whose T-cell acute lymphoblastic leukemia has come back or hasn't responded to standard treatment. The goal is to see if this combo can help when other treatments haven't worked.
Seongnam-siAges 19–80 - NCT06712407RecruitingPhase 4
Extended TARPEYO treatment for IgA nephropathy
This study tests whether taking TARPEYO (budesonide) for longer than 9 months is safe and effective for adults with IgA nephropathy. It's for people who have already completed a 9-month course of TARPEYO and are on stable blood pressure medication.
Birmingham, AlabamaAges 18 years+ - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06713512Recruiting
Estrogen and its effect on lung tissue in obstructive lung disease
This study looks at how the hormone estrogen affects the lungs of people with asthma or COPD. It will help researchers understand why these diseases may be different in women.
LondonAges 18–99 - NCT06714149Recruiting
How nitrogen pollution affects pollen allergies
This study looks at how pollution from nitrogen in the environment affects pollen allergies in Belgium. It may help explain why your allergy symptoms change depending on where you live.
Leuven, Vlaams-BrabantAges 18 years+ - NCT06714838RecruitingPhase 3
Rituximab for remission in chronic inflammatory demyelinating polyneuropathy
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
AmsterdamAges 18–80 - NCT06715046Recruiting
Blood DNA test after stem cell transplant
This study checks if looking at DNA in your blood can help doctors see how well your stem cell transplant is working and catch any problems early. It is for people with blood cancers getting a transplant from a donor.
Milan, MilanAges 18 years+ - NCT06715215Recruiting
Blood test study for immune thrombocytopenia
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
Sohag, SahagAges 1–50 - NCT06715436Recruiting
Ketogenic diet for multiple sclerosis
This study tests whether a ketogenic diet can help people with multiple sclerosis. You would follow a special high-fat, low-carb diet for a period, and the researchers will check its effects on your symptoms and overall health.
PaviaAges 18–60 - NCT06716164RecruitingEarly Phase 1
Experimental car-t cell therapy for relapsed b-cell lymphoma
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hangzhou, ZhejiangAges 19–70 - NCT06716450Recruiting
HIV and syphilis self-test study
This study tests a new self-test for HIV and syphilis that you can do yourself at a clinic or community site. It is for people who do not know if they have HIV or syphilis and have not tested positive before.
Victoria, British ColumbiaAges 18 years+ - NCT06716658RecruitingPhase 2
New targeted drug for certain T/NK-cell lymphomas
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06716814RecruitingPhase 3
Continuing efanesoctocog alfa after earlier trial
This study provides continued access to the clotting factor treatment efanesoctocog alfa for people who have already been getting it in a previous trial. It helps ensure you can keep using the medicine if it is working for you.
PlovdivAges 6 years+ - NCT06717113RecruitingEarly Phase 1
A new imaging test for multiple myeloma
This trial tests a special imaging dye that targets a protein called BCMA on multiple myeloma cells. It may help doctors see and diagnose the disease more clearly during bone marrow or tissue biopsies.
Beijing, Beijing MunicipalityAges 18–80 - NCT06717581Recruiting
Drug interaction study for older people with HIV
This study looks at how other medicines you take for conditions like high blood pressure, diabetes, or cholesterol might interact with your HIV medication (Biktarvy) if you are 60 or older. The goal is to learn how to better manage your overall health.
BolognaAges 18 years+ - NCT06717815RecruitingPhase 1/Phase 2
Study of IPG11406 for lupus kidney disease
This trial tests a new drug called IPG11406 for people with active lupus nephritis, a type of kidney inflammation caused by lupus. It aims to see if the drug can help reduce kidney damage and improve symptoms.
Hefei, AnhuiAges 18–70 - NCT06717893Recruiting
Type 1 diabetes study in children and teens
This study looks at the health records of children and teens newly diagnosed with type 1 diabetes to understand their insulin needs at the start and over the first year. It may help doctors better predict and manage insulin doses for future patients.
BolognaAges Up to 14 years - NCT06718244RecruitingPhase 2
CNCT19 for B-ALL with minimal remaining cancer after first remission
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT06718270RecruitingEarly Phase 1
Study of CT0596 for Relapsed or Refractory Myeloma
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06718569Recruiting
Pain in Inflammatory Joint Diseases
This study looks at pain in people with inflammatory joint diseases. It aims to understand how pain changes when you start or switch to a newer type of arthritis medication.
OsloAges 18 years+ - NCT06718920Recruiting
Childhood experiences and quality of life in MS
This study looks at how difficult childhood experiences may affect the quality of life and coping skills of people with multiple sclerosis. By answering questionnaires, you can help researchers understand these connections and find better ways to support patients.
Rome, RMAges 18 years+ - NCT06720870Recruiting
Siltuximab for Castleman's disease: a real-world study
This trial is looking back at the medical records of people with a rare condition called Castleman's disease to see how well the drug Siltuximab worked for them in everyday hospital care, not in a research setting. The goal is to learn more about how safe and effective the drug can be for patients in real life.
Bologna, BolognaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.